Real-world treatment patterns, comorbidities, and disease-related complications in patients with multiple myeloma in the United States
Authors:
- 11 November 2015
- journal article
- Published by Informa Healthcare in Current Medical Research and Opinion
- Vol. 32 (1) , 95-103
Abstract
Real-world treatment patterns, comorbidities, and disease-related complications in patients with multiple myeloma in the United States. . ???aop.label???. doi: 10.1185/03007995.2015.1105202Keywords
This publication has 16 references indexed in Scilit:
- Lenalidomide and Dexamethasone in Transplant-Ineligible Patients with MyelomaNew England Journal of Medicine, 2014
- International Myeloma Working Group Consensus Statement for the Management, Treatment, and Supportive Care of Patients With Myeloma Not Eligible for Standard Autologous Stem-Cell TransplantationJournal of Clinical Oncology, 2014
- Persistent Overall Survival Benefit and No Increased Risk of Second Malignancies With Bortezomib-Melphalan-Prednisone Versus Melphalan-Prednisone in Patients With Previously Untreated Multiple MyelomaJournal of Clinical Oncology, 2013
- International Myeloma Working Group consensus approach to the treatment of multiple myeloma patients who are candidates for autologous stem cell transplantationBlood, 2011
- Multiple MyelomaNew England Journal of Medicine, 2011
- Shifts in the Therapeutic Paradigm for Patients Newly Diagnosed with Multiple Myeloma: Maintenance Therapy and Overall SurvivalClinical Cancer Research, 2011
- Improved survival in multiple myeloma and the impact of novel therapiesBlood, 2008
- New Drugs for MyelomaThe Oncologist, 2007
- Superiority of thalidomide and dexamethasone over vincristine-doxorubicindexamethasone (VAD) as primary therapy in preparation for autologous transplantation for multiple myelomaBlood, 2005
- Multiple MyelomaNew England Journal of Medicine, 2004